Affimed

AFMD NASDAQ
2.680
-0.120
-4.29%
After Hours: 2.680 0 0.00% 16:00 08/23 EDT
Open
2.800
Prev Close
2.800
High
2.814
Low
2.670
Volume
334.50K
Avg Vol (3M)
853.10K
52 Week High
7.35
52 Week Low
1.550
% Turnover
0.54%
Market Cap
167.34M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Affimed AFMD stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes FM13, AFM11, AFM21, AFM22, AFM24, TandAb and Trispecific Abs. It has started recruitment for Phase IIa clinical trial of AFM13 in patients with Hodgkin Lymphoma. It has initiated a Phase I clinical trial of AFM11 in patients with non-Hodgkin Lymphoma. AFM21 is in preclinical development. AFM22, which is an Epidermal Growth Factor Receptor variant III (EGFRvIII)/CD16A NK-cell TandAb is in preclinical development. AFM24 is an additional CD16A NK-cell TandAb targeting a validated solid tumor target, EGFR-wild type. It is developing Trispecific Abs for treating multiple myeloma, and CD33/CD3-specific T-cell TandAb to treat acute myeloid leukemia.
MORE >

Recently

Name
Price
%Change